Kannalife Sciences, Inc.
Pharmaceutical ManufacturingPennsylvania, United States2-10 Employees
Kannalife Sciences, Inc., a subsidiary of Neuropathix, Inc., is a pioneering biopharmaceutical company advancing globally patented, synthetic cannabinoid-inspired therapeutics for the treatment of neurodegenerative and neuropathic diseases. Headquartered at the Pennsylvania Biotechnology Center, Kannalife’s lead candidate, KLS-13019, targets key drivers of neuroinflammation and mitochondrial dysfunction, including mNCX-1, GPR55, and the NLRP3 inflammasome. The company’s innovation has been recognized through substantial non-dilutive funding, including a $1.5 million grant from The Michael J. Fox Foundation for Parkinson’s Research and $3.3 million from the NIH HEAL Initiative to support IND-enabling studies to advance KLS-13019 toward clinical trials.